Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 inhibitor + carboplatin + albumin-bound paclitaxel
- Development stage
- Unknown
- Lead developer
- Sun Yat-Sen Memorial Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This is a neoadjuvant chemoimmunotherapy regimen consisting of a Programmed Cell Death Protein 1 (PD-1) inhibitor combined with the platinum-based chemotherapy agent carboplatin and the microtubule inhibitor albumin-bound paclitaxel. It is being evaluated by Sun Yat-Sen Memorial Hospital for the treatment of resectable locally advanced oral squamous cell carcinoma (OSCC). The PD-1 inhibitor works by blocking the interaction between PD-1 on T cells and its ligands (PD-L1/PD-L2) on tumor cells, thereby restoring anti-tumor immune responses. Carboplatin induces DNA cross-linking, interfering with DNA repair and synthesis, while albumin-bound paclitaxel inhibits microtubule disassembly, leading to cell cycle arrest and apoptosis. This combination aims to reduce tumor size and improve surgical outcomes and survival in patients with advanced head and neck cancers.
- Other names
- NACIneoadjuvant chemoimmunotherapy
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on PD-1 inhibitor + carboplatin + albumin-bound paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 inhibitor + carboplatin + albumin-bound paclitaxel.